Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) EBIT: 2009-2025

Historic EBIT for China Pharma Holdings (CPHI) over the last 17 years, with Sep 2025 value amounting to -$628,145.

  • China Pharma Holdings' EBIT rose 42.12% to -$628,145 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.2 million, marking a year-over-year increase of 29.33%. This contributed to the annual value of -$4.6 million for FY2024, which is 66.76% down from last year.
  • China Pharma Holdings' EBIT amounted to -$628,145 in Q3 2025, which was up 3.68% from -$652,120 recorded in Q2 2025.
  • China Pharma Holdings' EBIT's 5-year high stood at -$397,479 during Q1 2023, with a 5-year trough of -$1.4 million in Q2 2024.
  • For the 3-year period, China Pharma Holdings' EBIT averaged around -$852,688, with its median value being -$758,618 (2025).
  • In the last 5 years, China Pharma Holdings' EBIT tumbled by 1,104.13% in 2021 and then skyrocketed by 56.40% in 2023.
  • Over the past 5 years, China Pharma Holdings' EBIT (Quarterly) stood at -$648,690 in 2021, then slumped by 80.21% to -$1.2 million in 2022, then decreased by 1.32% to -$1.2 million in 2023, then fell by 0.97% to -$1.2 million in 2024, then soared by 42.12% to -$628,145 in 2025.
  • Its EBIT stands at -$628,145 for Q3 2025, versus -$652,120 for Q2 2025 and -$758,618 for Q1 2025.